Literature DB >> 22777337

The performance of process measures in hepatitis C.

Fasiha Kanwal1, Tuyen Hoang, Jennifer Kramer, Timothy Chrusciel, Hashem El-Serag, Jason A Dominitz, Steven M Asch.   

Abstract

OBJECTIVES: Previous evaluations regarding the extent to which standard chronic hepatitis C virus (HCV) care processes are delivered during routine clinical care are scant and have primarily relied on automated data--the validity of which is unknown.
METHODS: We examined adherence to 24 explicit modified Delphi panel-derived HCV-specific process measures in a cohort of 122,744 patients enrolled in the automated Veterans Administration HCV Clinical Case Registry between 2000 and 2006. We reviewed medical charts of 717 patients to compare the agreement between Registry and charts. We also estimated the effect of justifiable exceptions on measured performance in HCV by determining the proportion of patients who failed a measure but met a valid exception (i.e., patient refusal, outside care, or treatment contraindications).
RESULTS: The percentage of patients who met the individual measures varied. For example, 74% of patients received HCV genotype testing, 23% received antiviral treatment, 28% received liver biopsy, and 16% received hepatitis A vaccination. We found excellent agreement between the Registry and charts in all measures (agreement coefficients >0.75). However, exceptions to indicated care documented in charts were common for genotype testing, liver biopsy, and antiviral treatment. After accounting for these exceptions, the measure rates increased from 75 to 93% for genotype testing, 31 to 50% for liver biopsy, and from 26 to 64% for antiviral treatment. Treatment contraindications were the most common reasons for not meeting indicated care.
CONCLUSIONS: Automated data missed several exceptions to care that are documented only in providers' notes, thus underestimating process of care. These results have implications for future quality assessment initiatives-most of which will likely rely on automated data for process-based quality reporting. After accounting for automated data and medical record reviews, vaccinations and antiviral treatment rates in the Veterans Administration left room for improvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22777337     DOI: 10.1038/ajg.2012.201

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

2.  Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C.

Authors:  John Davison; Amy O'Shea; Nancee Waterbury; Yolanda Villalvazo
Journal:  J Community Health       Date:  2018-12

3.  Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

Authors:  M Lin; J Kramer; D White; Y Cao; S Tavakoli-Tabasi; S Madu; D Smith; S M Asch; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2017-09-26       Impact factor: 8.171

4.  Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.

Authors:  Amit G Singal; Xilong Li; Jasmin Tiro; Pragathi Kandunoori; Beverley Adams-Huet; Mahendra S Nehra; Adam Yopp
Journal:  Am J Med       Date:  2014-08-10       Impact factor: 4.965

Review 5.  Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States.

Authors:  D Tan; A Yopp; M S Beg; P Gopal; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

6.  Process of care for hepatitis C infection is linked to treatment outcome and virologic response.

Authors:  Fasiha Kanwal; Tuyen Hoang; Timothy Chrusciel; Jennifer R Kramer; Hashem B El-Serag; Jason A Dominitz; Steven M Asch
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-25       Impact factor: 11.382

7.  Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.

Authors:  J K Hou; J R Kramer; P Richardson; S Sansgiry; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2012-10-14       Impact factor: 8.171

8.  Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Hashem B El-Serag; Susan Frayne; Jack Clark; Yumei Cao; Thomas Taylor; Donna Smith; Donna White; Steven M Asch
Journal:  Clin Infect Dis       Date:  2016-04-30       Impact factor: 9.079

9.  Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection.

Authors:  Fasiha Kanwal; Tuyen Hoang; Timothy Chrusciel; Jennifer R Kramer; Hashem B El-Serag; Janet Durfee; Jason A Dominitz; Elizabeth M Yano; Steven M Asch
Journal:  Dig Dis Sci       Date:  2013-08-10       Impact factor: 3.199

10.  Quality of Care Provided by Hepatologists to Patients with Cirrhosis at Three Parallel Health Systems.

Authors:  Seth N Sclair; Olveen Carrasquillo; Frank Czul; Juan P Trivella; Hua Li; Lennox Jeffers; Paul Martin
Journal:  Dig Dis Sci       Date:  2016-06-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.